Oral bioavailability of P-glycoprotein substrate drugs do not differ between ABCB1-1Δ and ABCB1 wild type dogs

Journal of Veterinary Pharmacology and Therapeutics

Volumn 33, Issue 5, 2010, Pages 453-460

  Mealey, K L ^a   Waiting, D ^a   Raunig, D L ^b   Schmidt, K R ^b   Nelson, F R ^b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; DIAZEPAM; GLYCOPROTEIN P; LOPERAMIDE; MULTIDRUG RESISTANCE PROTEIN 1; NELFINAVIR; QUINIDINE GLUCONATE; QUINIDINE SULFATE; VETERINARY DRUG;

ABCB 1 GENE; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; GENOTYPE; INTESTINE ABSORPTION; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NULL ALLELE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDIARRHEALS; ANTIMALARIALS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; CYCLOSPORINE; DIAZEPAM; DOGS; ENZYME INHIBITORS; FEMALE; GENOTYPE; HIV PROTEASE INHIBITORS; LOPERAMIDE; MALE; NELFINAVIR; P-GLYCOPROTEIN; QUINIDINE; SUBSTRATE SPECIFICITY;

ANIMALIA; CANIS FAMILIARIS;

EID: 77956622410     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2010.01170.x     Document Type: Article

References (40)

1. Adachi, Y., Suzuki, H. Sugiyama, Y. (2003) Quantitative evaluation of the function of small intestinal P-glycoprotein: comparative studies between in situ and in vitro. Pharmaceutical Research, 20, 1163 1169.
2. Bardelmeijer, H.A., Ouwehand, M., Buckle, T., Huisman, M.T., Schellens, J.H., Beijnen, J.H. van Tellingen, O. (2002) Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Research, 62, 6158 6164.
3. Bouer, R., Barthe, L., Philibert, C., Tournaire, C., Woodley, J. Houin, G. (1999) The roles of P-glycoprotein and intracellular metabolism in the intestinal absorption of methadone: in vitro studies using the rat everted intestinal sac. Fundamental Clinical Pharmacology, 13, 494 500.
4. Chen, C., Liu, X. Smith, B.J. (2003) Utility of Mdr1-gene deficient mice in assessing the impact of P-glycoprotein on pharmacokinetics and pharmacodynamics in drug discovery and development. Current Drug Metabolism, 4, 272 291.
5. Chiou, W.L., Chung, S.M., Wu, T.C. Ma, C. (2001) A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. International Journal of Clinical Pharmacological Therapy, 39, 93 101.
6. Cordon-Cardo, C., O'Brien, J.P., Casals, D., Rittman-Grauer, L., Biedler, J.L., Melamed, M.R. Bertino, J.R. (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proceedings of the National Academy of Sciences USA, 86, 695 698.
7. Cornwell, M.M. (1991) Molecular biology of P-glycoprotein. Cancer Treatment and Research, 57, 37 56.
8. Davies, B. Morris, T. (1993) Physiological parameters in laboratory animals and humans. Pharmaceutical Research, 10, 1093 1095.
9. Fossum, T.W 2002) Small animal surgery, 2nd edn, 716 759. Surgery of the Upper Respiratory System, Mosby, St Louis, MO. Ref Type: Serial (Book,Monograph).
10. Gerloff, T., Schaefer, M., Johne, A., Oselin, K., Meisel, C., Cascorbi, I. Roots, I. (2002) MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. British Journal of Clinical Pharmacology, 54, 610 616.
11. Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H.P., Brockmoller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M. Brinkmann, U. (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proceedings of the National Academy of Sciences USA, 97, 3473 3478.
12. Hori, R., Okamura, N., Aiba, T. Tanigawara, Y. (1993) Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney. Journal of Pharmacology and Experimental Therapeutics, 266, 1620 1625.
13. Juranka, P.F., Zastawny, R.L. Ling, V. (1989a) P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB Journal, 3, 2583 2592.
14. Kim, R.B., Fromm, M.F., Wandel, C., Leake, B., Wood, A.J., Roden, D.M. Wilkinson, G.R. (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. Journal of Clinical Investigation, 101, 289 294.
15. Kitamura, Y., Koto, H., Matsuura, S., Kawabata, T., Tsuchiya, H., Kusuhara, H., Tsujimoto, H. Sugiyama, Y. 2008) Modest effect of impaired function of P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in Collie dogs. Drug Metabolism and Disposition, 36, 807 810.
16. Kwei, G.Y., Alvaro, R.F., Chen, Q., Jenkins, H.J., Hop, C.E., Keohane, C.A., Ly, V.T., Strauss, J.R., Wang, R.W., Wang, Z., Pippert, T.R. Umbenhauer, D.R. (1999) Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein. Drug Metabolism and Disposition, 27, 581 587.
17. Lankas, G.R., Wise, L.D., Cartwright, M.E., Pippert, T. Umbenhauer, D.R. (1998) Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reproductive Toxicology, 12, 457 463.
18. Lee, K., Ng, C., Brouwer, K.L. Thakker, D.R. (2002) Secretory transport of ranitidine and famotidine across Caco-2 cell monolayers. Journal of Pharmacology and Experimental Therapeutics, 303, 574 580.
19. Li, M., Hurren, R., Zastawny, R.L., Ling, V. Buick, R.N. (1999) Regulation and expression of multidrug resistance (MDR) transcripts in the intestinal epithelium. British Journal of Cancer, 80, 1123 1131.
20. Lown, K.S., Mayo, R.R., Leichtman, A.B., Hsiao, H.L., Turgeon, D.K., Schmiedlin-Ren, P., Brown, M.B., Guo, W., Rossi, S.J., Benet, L.Z. Watkins, P.B. (1997) Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clinical Pharmacology and Therapeutics, 62, 248 260.
21. Mealey, K.L., Bentjen, S.A., Gay, J.M. Cantor, G.H. (2001) Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics, 11, 727 733.
22. Mealey, K.L., Greene, S., Bagley, R., Gay, J.M., Tucker, R.L., Gavin, P.R., Schmidt, K. Nelson, F.R. 2008) P-glycoprotein contributes to the blood-brain, but not blood-CSF, barrier in a spontaneous canine P-glycoprotein knockout model. Drug Metabolism and Disposition, 36, 1073 1079.
23. Melaine, N., Lienard, M.O., Dorval, I., Le Goascogne, C., Lejeune, H. Jegou, B. (2002) Multidrug resistance genes and p-glycoprotein in the testis of the rat, mouse, Guinea pig, and human. Biology of Reproduction, 67, 1699 1707.
24. Neff, M.W., Robertson, K.R., Wong, A.K., Safra, N., Broman, K.W., Slatkin, M., Mealey, K.L. Pedersen, N.C. (2004) Breed distribution and history of canine mdr1-1Delta, a pharmacogenetic mutation that marks the emergence of breeds from the collie lineage. Proceedings of the National Academy of Sciences of the USA, 101, 11725 11730.
25. Patel, J. Mitra, A.K. (2001) Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs. Pharmacogenomics, 2, 401 415.
26. Saitoh, H., Saikachi, Y., Kobayashi, M., Yamaguchi, M., Oda, M., Yuhki, Y., Achiwa, K., Tadano, K., Takahashi, Y. Aungst, B.J. (2006) Limited interaction between tacrolimus and P-glycoprotein in the rat small intestine. European Journal of Pharmaceutical Sciences, 28, 34 42.
27. Sakaeda, T. (2005) MDR1 genotype-related pharmacokinetics: fact or fiction? Drug Metabolism and Pharmacokinetics, 20, 391 414.
28. Schinkel, A.H., Wagenaar, E., van Deemter, L., Mol, C.A. Borst, P. (1995a) Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. Journal of Clinical Investigation, 96, 1698 1705.
29. Schwarz, U.I., Gramatte, T., Krappweis, J., Berndt, A., Oertel, R., von Richter, O. Kirch, W. (1999) Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans. Clinical Pharmacology and Therapeutics, 65, 283 290.
30. Seelig, A. (1998) A general pattern for substrate recognition by P-glycoprotein. European Journal of Biochemistry, 251, 252 261.
31. Sparreboom, A., van Asperen, J., Mayer, U., Schinkel, A.H., Smit, J.W., Meijer, D.K., Borst, P., Nooijen, W.J., Beijnen, J.H. van Tellingen, O. (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proceedings of the National Academy of Sciences USA, 94, 2031 2035.
32. Suzuyama, N., Katoh, M., Takeuchi, T., Yoshitomi, S., Higuchi, T., Asashi, S. Yokoi, T. (2007) Species differences of inhibitory effects on P-glycoprotein-mediated drug transport. Journal of Pharmaceutical Sciences, 96, 1609 1618.
33. Tahara, H., Kusuhara, H., Fuse, E. Sugiyama, Y. (2005) P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion. Drug Metabolism and Disposition, 33, 963 968.
34. Tayrouz, Y., Ganssmann, B., Ding, R., Klingmann, A., Aderjan, R., Burhenne, J., Haefeli, W.E. Mikus, G. (2001) Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement. Clinical Pharmacology and Therapeutics, 70, 405 414.
35. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M.M., Pastan, I. Willingham, M.C. (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proceedings of the National Academy of Sciences of the USA, 84, 7735 7738.
36. Troutman, M.D. Thakker, D.R. (2003) Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharmaceutical Research, 20, 1200 1209.
37. Wandel, C., Kim, R., Wood, M. Wood, A. (2002) Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology, 96, 913 920.
38. Westphal, K., Weinbrenner, A., Giessmann, T., Stuhr, M., Franke, G., Zschiesche, M., Oertel, R., Terhaag, B., Kroemer, H.K. Siegmund, W. (2000) Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clinical Pharmacology and Therapeutics, 68, 6 12.
39. Yamaguchi, H., Yano, I., Saito, H. Inui, K. (2002) Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo. Journal of Pharmacology and Experimental Therapeutics, 300, 1063 1069.
40. Zhang, K., Kohno, S., Kuroha, M., Kokue, E. Shimoda, M. (2006) Clinical oral doses of dexamethasone decreases intrinsic clearance of quinidine, a cytochrome P450 3A substrate in dogs. Journal of Veterinary Medical Sciences, 68, 903 907.